Roman Butler Fullerton & Co. Has $236,000 Stake in Thermo Fisher Scientific Inc. $TMO

Roman Butler Fullerton & Co. boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.5% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 583 shares of the medical research company’s stock after buying an additional 91 shares during the period. Roman Butler Fullerton & Co.’s holdings in Thermo Fisher Scientific were worth $236,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of TMO. Nuveen LLC acquired a new stake in Thermo Fisher Scientific in the 1st quarter valued at $532,360,000. EdgePoint Investment Group Inc. bought a new position in Thermo Fisher Scientific in the 1st quarter valued at $172,139,000. Cohen Investment Advisors LLC raised its position in Thermo Fisher Scientific by 6,655.5% in the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company’s stock valued at $167,271,000 after purchasing an additional 331,180 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Thermo Fisher Scientific by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock valued at $1,368,859,000 after purchasing an additional 329,974 shares during the last quarter. Finally, Auto Owners Insurance Co raised its position in Thermo Fisher Scientific by 6,773.5% in the 1st quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company’s stock valued at $143,309,000 after purchasing an additional 283,810 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on TMO. Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, October 12th. Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday. Raymond James Financial restated an “outperform” rating and set a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday. Nineteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $595.75.

Thermo Fisher Scientific Trading Up 0.8%

NYSE TMO opened at $571.94 on Friday. The stock has a 50-day simple moving average of $502.38 and a 200 day simple moving average of $452.23. The company has a market capitalization of $215.97 billion, a PE ratio of 33.04, a P/E/G ratio of 3.25 and a beta of 0.77. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm’s revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 400 shares of the stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,666 shares of company stock valued at $13,990,971 in the last quarter. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.